A sequential classification rule based on multiple quantitative tests in the absence of a gold standard by Zhang, Jingyang et al.
Research Article
Statistics
in Medicine
Received XXXX
(www.interscience.wiley.com) DOI: 10.1002/sim.0000
A sequential classification rule based on multiple
quantitative tests in the absence of a gold
standard
Jingyang Zhang1∗, Ying Zhang2,3, Kathryn Chaloner4,5 and Jack T. Stapleton6
In many medical applications, combining information from multiple biomarkers could yield a better diagnosis than
any single one on its own. When there is a lack of a gold standard, an algorithm of classifying subjects into the case
and non-case status is necessary for combining multiple markers. The aim of this paper is to develop a method to
construct a composite test from multiple applicable tests and derive an optimal classification rule under the absence
of a gold standard. Rather than combining the tests, we treat the tests as a sequence. This sequential composite test
is based on a mixture of two multivariate normal latent models for the distribution of the test results in case and
non-case groups and the optimal classification rule is derived returning the greatest sensitivity at a given specificity.
This method is applied to a real data example and simulation studies have been carried out to assess the statistical
properties and predictive accuracy of the proposed composite test. This method is also attainable to implement
nonparametrically. Copyright c© 2015 John Wiley & Sons, Ltd.
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1. Introduction
This work is motivated by some methodological research in HIV/AIDS studies. Some studies have observed that co-
infection of a human RNA virus, GB virus C (GBV-C), can prolong the survival for HIV patients [1–8]. GBV-C is not
currently known to definitely cause any disease although a recent observational study suggested a potential link between
GBV-C and non-Hodgkins lymphoma [9]. Approximately 14%-43% of the individuals with HIV infection have the GBV-
C viraemia [10,11]. Some studies also found an association between GBV-C and improved response to HIV therapy [11].
The mechanism is still under investigation [12–14]. GBV-C viraemia is shown to be cleared in a great portion of patients
from several months to several years [15, 16], and antibodies that are directed against the viral envelope glycoprotein 2
(E2) develop [17]. Hence the E2 antibodies are a marker of past GBV-C infection [18, 19]. An association between the
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E2 antibodies and the prolonged survival from HIV in subjects without GBV-C viraemia has also been observed [5]. To
detect the presence of E2 antibodies in human serum samples, one commonly used method is through the Enzyme Linked
Immunosorbent Assay (ELISA); however, there is no commercial and validated test available for the E2 antibodies. In the
motivating example from Dr. Jack Stapleton’s lab at the University of Iowa, a total of 100 independent blood specimens
obtained from HIV infected subjects were tested by two ELISAs, which are not perfect and return a quantitative result with
respect to the concentration of the E2 antibodies. The primary goal of the paper is to establish and evaluate a composite
diagnostic test based on the two ELISAs in the absence of the true antibody status and any other reference test.
In diagnostic testing, a gold standard is defined as a reference test or a benchmark that is assumed 100% accurate in
discriminating case from non-case. When a gold standard is available, the accuracy of a single diagnostic test has been
well studied. The accuracy of a binary test is evaluated by the true positive fraction (TPF, or sensitivity) and false positive
fraction (FPF, or 1-specificity). For a continuous-scale test, different binary tests can be induced by selecting different
threshold values. At each threshold, a pair of TPF and FPF is obtained, and the curve that connects all pairs of TPF and
FPF over all possible thresholds, which is the receiver operating characteristic (ROC) curve, is a commonly used tool to
evaluate a continuous marker. These are detailed in Zhou et. al. [20] and Pepe [21].
When there are multiple imperfect tests available, combining them into one composite test may yield a better diagnostic
test than any single test. For continuous tests, a simple case is to repeat testing on a single test. Tolley et. al. [22] and
Murtaugh [23] consider the scenario of repeated applications of the same continuous test. At each test application, the
threshold remains the same. For a set of different tests, various composite tests exist for a given overall specificity. The
most straightforward way is to form a linear combination. Suppose X ∼ N(µx,Σx) represents the test results in the case
population and Y ∼ N(µy,Σy) represents the test results in the non-case population. The linear composite rule is then
based on U = aTX and V = aTY . Su and Liu [24] justifies that the linear discriminant function is the optimal linear
combination that produces the maximum AUC in this case, i.e., the coefficient for the best linear combination is
a0 ∝ (Σx +Σy)−1(µy − µx).
The linear combination is easy to implement and straightforward to interpret, however, the optimality is only guaranteed
when the results are normal and homoscedastic.
Rather combining the multiple tests in parallel, we could also treat them as a sequence. Thompson [25] considers the
combination of a sequence of tests. The sequence of tests can be the repeated applications of the same test on the same
subject, or different tests simultaneously. The development of the sequential rule does not limit to the linear combination
of multiple tests, and the application of the sequential rule on a new population does not require the practice of all tests on
each subject. Two main concepts are usually used to define the sequential rule [26,27]. The first one is “believe negative”
(BN), where individuals who have negative diagnosis from any particular test will not receive subsequent tests. The other
one is “believe positive” (BP), where individuals who have positive diagnosis from any particular test will not receive sub
sequential tests. In this work, we will focus on the sequential rule defined by the BP approach. Thompson [25] provides
the evaluation of accuracy of a sequence of tests. For two continuous tests X1 and X2, based on the BP rule, an individual
is defined as positive if X1 > c1,p1 or X2 > c2,p2 , where ci,pi is the pith percentile of the distribution of Xi in non-case
population for i = 1, 2. The ROC curve of the sequence test as a function of an overall false positive fraction s can be
expressed as (1) [25].
ROCX1∨X2(s | p1) = 1− F2.1D
(
F−1
2.1D¯
(
1− s
p1
))
F1D(c1p1), (1)
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where F2.1D and F2.1D¯ are the conditional distribution functions for X2 given X1 < c1p1 in the case and non-case
populations. The accuracy of the test sequence could be assessed by the MaxROC curve expressed as
MaxROC(s) = max
p1
ROCX1∨X2(s | p1),
so that the sensitivity for any given specificity will be at least as high as that for either of the individual tests, applied on
its own with the same threshold. The choice of threshold in implementation, however, is not addressed in this paper.
Both the aforementioned combinations are based on the knowledge of a gold standard, or the true case status. In
practice, such information is not always available, because it may be difficult or even impossible to determine the true
case status, and even the available reference test against which new tests are compared is subject to error. Kraemer [28]
argues the opinion that the true case status is almost never ascertained. For ordinal or continuous-scale tests, the sensitivity
and specificity are computed based on a certain classification rule with a specific threshold value, hence are dependent
on the choice of the classification rule. When the true case status is unknown and there is no gold standard or even an
imperfect binary reference test, like the E2 antibodies data example, a decision rule established from multiple imperfect
test needs to be studied [21]. The statistical issues in diagnostic testing without a gold standard are addressed by Hui
and Walter [29] mainly focusing on binary tests and summarized by Hui and Zhou [30] with many available methods
for quantitative tests. Using the finite mixture model for continuous data , one could acquire the pointwise estimates of
the sensitivity and specificity for a continuous-scale test over all possible threshold values by the maximum likelihood
method [31]. The estimated ROC curve composed by all estimated sensitivities and specificities, however, may not retain
the monotonicity, as in Figures. 2, 3, 4, 5 of [31]. Henkelman et al. [32] propose an estimation of the ROC curve of an
ordinal-scale test via a mixture of multivariate normal latent model and Choi et al. [33] provide a parametric Bayesian
method for a continuous-scale test under the same distributional assumption. Both methods guarantee that the estimated
ROC curve is monotone. The ROC curve can also be estimated nonparametrically instead of assuming the multivariate
normal distributions as proposed by Hall and Zhou [34] in which the monotonicity of the estimated ROC curve is assured
without any parametric assumptions on the distributions of the test results.
The methods above primarily focus on the evaluation of diagnostic tests when there is no definitive diagnosis or a gold
standard, rather on the formulation of a decision rule by combining several available continuous markers. In fact, under
some assumptions, those methods could be extended to develop a decision rule from multiple continuous-scale tests. For
example, Su-Liu’s linear discriminant method is still applicable with the parameters in the normal distributions estimated
through the maximum likelihood method using the EM algorithm [35]. Our aim in this paper is to derive an optimal
composite test in a sequential way. The optimal sequential composite test is described in Section 2, and applied to the
motivating ELISA data in Section 3. The statistical properties are explored through simulation studies in Section 4. We
conclude this paper by discussion in Section 5.
2. Optimal sequential composite test without a gold standard
For simplicity in illustration, suppose that there are two quantitative diagnostic tests on each subject and for each test, a
greater value of the result indicates a larger chance of case. Denote Xi as the random variable representing the result from
test i for i = 1, 2 and D as the random variable indicating the case presence, with D = 1 meaning case present and D = 0
meaning case absent. Moreover, F1 and F0 are the joint distribution functions of X = (X1, X2) for the case and non-case
populations, respectively, and f1 and f0 are the corresponding probability density functions.
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2.1. Model setup
Suppose Test 1 is superior to Test 2 judged by a greater value of AUC. The decision rule driven by the sequential composite
test is determined by a pair of cut-off values (C1, C2) such that:
1. if X1 > C1, then this subject is classified as positive for the study event; else,
2. if X2 > C2, then classified as positive;
3. otherwise, classified as negative.
It is theoretically equivalent to the “believe the positive” (BP) rule defined in Marshall [26] and Politser [27] given the
threshold values C1 and C2.
Given the cut-off (C1, C2), the sensitivity and specificity for evaluating this composite test can be expressed as follows:
Sensitivity = Pr (Positive classification|case)
= Pr (X1 > C1|D = 1) + Pr (X1 ≤ C1, X2 > C2|D = 1)
= 1− F1(C1, C2). (2)
Specificity = Pr (Negative classification|control)
= Pr (X1 ≤ C1, X2 ≤ C2|D = 0)
= F0(C1, C2). (3)
Equations (2) and (3) are actually equivalent to (1) assuming that neither p1 nor p2 is pre-fixed.
We are searching for the optimal sequential composite test in the sense that it achieves the maximum sensitivity among
all the sequential composite tests whose specificity is fixed at p0. Based on (2) and (3), this task can be converted to a
constrained non-linear optimization problem:
min
F0(C1,C2)=p0
F1(C1, C2). (4)
An efficient algorithm for finding the optimal (C1, C2) in (4) is essential in the development of this sequential method.
2.2. Estimation and statistical inferences
2.2.1. MLE of multivariate normal model Suppose we have a sample of results from two quantitative diagnostic tests
X1,X2, · · · ,Xn that are assumed to be independent and identically distributed copies of X with distribution F . The
implementation of all the foregoing methods requires estimation of F1 and F0 from observed data in the first place. Here
we follow the set-up of Su and Liu’s method [24] for the distribution of the tests results X, i.e. X|D = 1 ∼ F1 ≡ N(µ1, V1)
and X|D = 0 ∼ F0 ≡ N(µ0, V0). A mixture distribution of F1 and F0 is adopted to model the observed data, that is
Fθ(·) = πF1,θ1(·) + (1− π)F0,θ0(·), (5)
where π is an unknown parameter indicating the mixture proportion, or equivalently, the case prevalence, and θ =
(π, θ1, θ0) = (π, (µ1, V1), (µ0, V0)) denotes the model parameters. The log-likelihood of the observed data can be
expressed as:
l(θ) =
n∑
k=1
lk(θ) =
n∑
k=1
log fθ(X1k, X2k)
=
n∑
k=1
log [πf1,θ1(X1k, X2k) + (1− π)f0,θ0(X1k, X2k)].
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Figure 1. Illustration of the search for the optimal (C1, C2) at a given specificity p0 . The solid line represents the contour curve given by F0(C1, C2) = p0 , and the dashed
lines represent the contour curves given by F1(C1, C2) = t at various values of t.
We note that if the gold standard does exist so that the exact memberships D = (D1, . . . , Dn) are known, the log
likelihood for the augmented data {(X1, D1), · · · , (Xn, Dn)} is given by
la(θ) =
n∑
k=1
Dk log πf1,θ1(X1k, X2k) + (1−Dk) log(1− π)f0,θ0(X1k, X2k) (6)
and
Pr(Dk = 1|(X1, · · · ,Xn); θ) = πf1,θ1(X1k, X2k)
πf1,θ1(X1k, X2k) + (1− π)f0,θ0(X1k, X2k)
.
Hence the MLE of the model parameters θˆn is easily computed using the EM algorithm [35] due to its numerical stability
and algorithmic convenience for this problem. The details of the EM algorithm are provided in Appendix A.
2.2.2. Computation of the optimal sequential composite test Under the normality assumption, the feasible set of (C1, C2)
defined by a given specificity F0(C1, C2) = p0 constitutes a convex contour curve [36]. When the diagnostic markers are
more variant for the case subjects, it is expected that the contour given by F1(C1, C2) = t is also convex but with less
curvature and moves towards the origin of (C1, C2) domain as t decreases. The optimization problem (4) can be illustrated
geometrically in Figure 1.
As seen in Figure 1, the constrained optimal value t corresponds to the value given by the contour that touches the
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contour of F0(C1, C2) = p0. The threshold vector (C1, C2) for the decision rule is simply the tangent point of the two
contour lines and can be uniquely determined. Therefore, the original optimization problem (4) is converted to solving the
system of bivariate nonlinear equations (7) for the tangent point of the contour lines of F1 and F0.
G(C, θ) =

F0,θ0(C1, C2) = p0
∂F1,θ1
∂C1
(C1, C2)
∂F0,θ0
∂C2
(C1, C2)− ∂F1,θ1
∂C2
(C1, C2)
∂F0,θ0
∂C1
(C1, C2) = 0.
(7)
The first equation represents the constraint given by the fixed specificity and the second equation reflects that the two
contour lines have the same gradient at the tangent point. The Newton-Raphson method with the step-halving line search
procedure is utilized to solve the system.
Let Cˆn = (Cˆ1n, Cˆ2n) denote the solution of (7) with the MLE of θ, θˆn = (θˆ1n, θˆ0n), then the sensitivity is estimated by
ŝenC = 1− F1,θˆ1n(Cˆ1n, Cˆ2n).
2.2.3. Asymptotic properties Suppose θ0 is the true vector of the model parameters under the mixture of bivariate normal
distribution. Assuming that the regularity conditions for MLE hold, it is known that as n→∞, θˆn →P θ0, and
√
n
(
θˆn − θ0
)
→d N(0, I−1),
where I is the Fisher information matrix given by −E
[
∂2
∂θ2
l1(θ)
∣∣∣ θ0] [37].
For the optimal sequential composite test, let C0 = (C10, C20) denote the solution of the system (7) under θ = θ0, then
the true sensitivity is senC = 1− F1,θ10(C10, C20). The estimated sensitivity ŝenC is consistent and asymptotically normal
under the mild condition (8) given in Theorem 2.1. The proof of the theorem is also deferred to Appendix B
Theorem 2.1 If F0 and F1 are continuously differentiable with respect to C = (C1, C2) and θ and satisfy the following
inequality (8) at C0 and θ0,[
∂2F1
∂C1∂C2
∂F0
∂C2
+
∂F1
∂C1
∂2F0
∂C2
2 −
∂2F1
∂C2
2
∂F0
∂C1
− ∂F1
∂C2
∂2F0
∂C1∂C2
]
∂F0
∂C1
−
[
∂2F1
∂C1
2
∂F0
∂C2
+
∂F1
∂C1
∂2F0
∂C1∂C2
− ∂
2F1
∂C1∂C2
∂F0
∂C1
− ∂F1
∂C2
∂2F0
∂C1
2
]
∂F0
∂C2
6= 0
(8)
then as sample size n→∞, √n (ŝenC − senC) converges to a normal distribution with mean 0 and variance given by
(B.1).
Remark 2.1 Condition (8) can be justified algebraically for bivariate normal random variables when F1 and F0 have a
different covariance matrix. In fact, the left side is the determinant of the Jacobian matrix of (7).
Remark 2.2 Although the asymptotic normality holds for the estimator under fairly mild conditions, the asymptotic
variance of the sensitivities is hard to estimate directly. Therefore for the inference, the standard error is estimated using
the nonparametric bootstrap method [38]. Specifically, 200 samples with the same size are drawn from the original data
with replacement. Each sample yields an estimated sensitivity at the given specificity from the estimated optimal sequential
composite test, and the standard error is then estimated by the standard deviation of the 200 estimated sensitivities.
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3. An analysis of the ELISA data
The optimal sequential composite test based on the two ELISAs is applied to classify the 100 independent blood samples
for the presence of E2 antibody in the motivating data example. Figure 2 presents a scatter plot of the results from the two
ELISAs. We fit the data by a mixture of two bivariate normal distributions: N(µ1, V1) and N(µ0, V0), and obtain the MLE
of the parameters as µˆ1 = (1.01, 0.84)T , µˆ0 = (0.16, 0.24)T , and
Vˆ1 =
(
0.54 0.22
0.22 0.40
)
, Vˆ0 =
(
0.004 0.001
0.001 0.017
)
.
Assuming the mixture of two bivariate normal models is true for this data example, the model-based estimated ROC
curves are depicted in Figure 3 for the two individual ELISAs. It is apparent in the figure that Test 1 is preferred to Test
2 as it has a higher sensitivity at any prefixed specificity from their ROC curves, and hence Test 1 is utilized as the initial
test for the proposed sequential composite test.
The optimal linear composite test for comparison is applicable here by extending the Su-Liu’s method [24] under the
assumption of normality. The technical details of the extended optimal linear composite test are referred to Zhang [39].
At the specificity of 90%, the ith sample is diagnosed as positive if X1i > 0.24 using test 1 alone, X2i > 0.41 using test
2 alone, 1.2X1i + 0.8X2i > 0.57 under the optimal linear composite test and X1i > 0.27 or X2i > 0.43 under the optimal
sequential composite test, where X1i and X2i are the results from test 1 and test 2 on the ith sample. If the future data set
is the same as the data used to derive the classification rules, the classifications based on both composite decision rules
are represented in Figure 2. The diagnoses from the two composite test do not disagree too much except that the linear
composite test tends to attribute more samples into the E2 antibody negative group. We also plot the ROC curves for
the two composite tests shown in Figure 3. Combining the two tests into a composite test does improve the discriminant
capability compared to any individual test. This improvement is possible because we allow the cut-off value for each of
the tests when used as a composite is different from the cut-off value when used individually. The improvement from the
linear composite test is not as substantial as the sequential composite test. It appears that the sequential test is superior
to the linear composite test at all values of specificity for this case. Moreover, the optimal sequential composite test only
needs 53% of the blood samples for the second test at average over 1000 bootstrap samples. This implies that under the
optimal sequential composite test, the probability that a patient needs to be tested by T2 is only about 50%. Hence it has
a profound significance in practice when the tests are expensive or present some strong side effects.
4. Simulation studies
4.1. Simulations on the model-based estimate of sensitivity for the proposed optimal sequential composite test
In this section, we conduct simulation studies to assess the statistical properties of the model-based sensitivity for the
proposed optimal sequential composite test. We generate two diagnostic markers for the case group from a bivariate
normal distribution N(µ1, V1) of
µ1 = (3.77, 1.51)
T and V1 =
(
3.97 0.69
0.69 1.42
)
,
and the markers for the non-case group from a bivariate normal distribution N(µ0, V0) of
µ0 = (2, 0.81)
T and V0 =
(
0.68 0.03
0.03 0.18
)
.
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Figure 2. Results from the two tests in 100 blood samples along with the optimal linear composite test and the optimal sequential composite test at specificity = 0.90.
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Figure 3. ROC curves for Test 2, Test 1, the optimal linear and sequential composite tests (from bottom to top).
The values of the parameters in the model are selected to mimic our motivating ELISA data example. A sample of 100
simulated data is shown in Figure 4. With the parameter values given above, the sensitivities at specificities 80% and 90%
are 71% and 64%, respectively, for Test 1, and 61% and 55% for Test 2. Test 1 is superior to Test 2.
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Figure 4. Scatter plot of a simulated data set of 100 subjects from the mixture model of two bivariate normal distributions with case prevalence as 0.5.
Three total sample sizes (100, 200 and 400) and two different case prevalence values (0.25 and 0.5) are examined,
respectively. At each combination of sample size and case prevalence, sample data are generated from the underlying
mixture of two bivariate normal models. The exact sensitivity of the optimal sequential composite test at a given specificity
is computed by solving the nonlinear system (7) with the bivariate normal distribution functions F0 and F1, and similarly,
the exact sensitivity of the optimal linear composite test is calculated using the true parameters in the bivariate normal
distributions as depicted by Su and Liu [24]. The model-based sensitivities are estimated with F1 and F0 replaced by
their MLE, Fˆ0 and Fˆ1. The standard error of the estimated sensitivity is obtained via the nonparametric bootstrap method
aforementioned and its 95% Wald confidence interval is constructed using the bootstrap standard error. Subsequently, the
bias, root mean square error (RMSE) and coverage probability of the 95% Wald confidence interval (CP) are calculated.
In addition, the empirical sensitivity (Esen) and specificity (Espe) are assessed since the true case status is known in
simulations. We repeat the Monte-Carlo simulation for 1000 times for each combination of the sample size and case
prevalence, and the results are summarized in Table 1.
Indicated by Table 1, the composite tests perform generally better than an individual test and the optimal sequential
composite test is superior to the optimal linear composite test in view of the sensitivities for a given specificity. Under the
correct normal mixture model, as the sample size increases, the bias of the model-based sensitivity tends to be negligible
and the coverage probability tends to arrive at the nominal value 95%, asserting the asymptotic properties declared by
Theorem 2.1. Our simulation study indicates for a study with small sample size of 100 as in the ELISA study in Section
3, the estimated sensitivity of the derived optimal sequential composite test is fairly accurate with a negligible bias as
illustrated by Table 1. The corresponding classification results are also reliable as illustrated by Table 1, because both the
empirical sensitivity and specificity closely agree to their designed values. However making the model-based inference
about the sensitivity needs a caution as the coverage probability is systematically lower than its target value (95%). It is
also inferred by the RMSE that the estimated sensitivity may be more precise with a higher case prevalence.
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Table 1. Summary of the simulation study at the given specificities based on 1000 Monte-Carlo samples in Section 4.1
with different total sample size N and different case prevalences π.
pi= 0.25
Test 1 alone
Specificity=80%, Sensitivity=0.705 Specificity=90%, Sensitivity=0.640
N Bias RMSE ESen ESpe CP Bias RMSE ESen ESpe CP
100 0.038 0.145 0.701 0.797 0.836 0.044 0.138 0.634 0.898 0.852
200 0.030 0.113 0.710 0.799 0.874 0.032 0.099 0.641 0.900 0.900
400 0.010 0.077 0.705 0.799 0.945 0.011 0.070 0.640 0.899 0.948
Optimal Linear Composite Test
Specificity=80%, Sensitivity=0.738 Specificity=90%, Sensitivity=0.682
N Bias RMSE ESen ESpe CP Bias RMSE ESen ESpe CP
100 0.058 0.149 0.742 0.793 0.741 0.064 0.141 0.685 0.892 0.771
200 0.039 0.113 0.743 0.797 0.844 0.042 0.100 0.686 0.897 0.867
400 0.014 0.074 0.739 0.798 0.942 0.014 0.066 0.684 0.898 0.946
Optimal Sequential Composite Test
Specificity=80%, Sensitivity=0.802 Specificity=90%, Sensitivity=0.750
N Bias RMSE ESen ESpe CP Bias RMSE ESen ESpe CP
100 0.037 0.119 0.794 0.794 0.777 0.044 0.116 0.741 0.895 0.822
200 0.026 0.092 0.800 0.798 0.856 0.029 0.084 0.747 0.899 0.872
400 0.009 0.063 0.800 0.798 0.941 0.010 0.059 0.749 0.899 0.947
pi= 0.5
Test 1 alone
Specificity=80%, Sensitivity=0.705 Specificity=90%, Sensitivity=0.640
N Bias RMSE ESen ESpe CP Bias RMSE ESen ESpe CP
100 0.031 0.120 0.698 0.800 0.882 0.034 0.111 0.630 0.896 0.903
200 0.018 0.084 0.708 0.799 0.929 0.019 0.072 0.642 0.899 0.939
400 0.006 0.065 0.704 0.800 0.957 0.007 0.060 0.637 0.900 0.961
Optimal Linear Composite Test
Specificity=80%, Sensitivity=0.738 Specificity=90%, Sensitivity=0.682
N Bias RMSE ESen ESpe CP Bias RMSE ESen ESpe CP
100 0.044 0.122 0.732 0.792 0.818 0.048 0.111 0.674 0.891 0.839
200 0.023 0.081 0.741 0.795 0.917 0.024 0.067 0.684 0.896 0.932
400 0.009 0.061 0.737 0.799 0.959 0.010 0.054 0.681 0.898 0.960
Optimal Sequential Composite Test
Specificity=80%, Sensitivity=0.802 Specificity=90%, Sensitivity=0.750
N Bias RMSE ESen ESpe CP Bias RMSE ESen ESpe CP
100 0.029 0.098 0.788 0.795 0.848 0.034 0.091 0.730 0.893 0.894
200 0.016 0.066 0.800 0.796 0.927 0.018 0.056 0.747 0.896 0.951
400 0.007 0.053 0.800 0.799 0.947 0.007 0.048 0.747 0.898 0.961
RMSE: Root mean square error. ESen/ESpe: Empirical sensitivity/specificity. CP: 95% confidence interval coverage probability.
4.2. Simulations on the classification accuracy of the proposed sequential composite test
In our motivating example, the true GBV-C status is unknown. A series of simulations are carried out to study the accuracy
and robustness of the prediction on a new dataset by the proposed composite classification rule. The simulation study is
designed in the following steps:
1. Simulate a training dataset by the two settings, respectively:
(a) The two markers follow the same mixture of two bivariate normal distributions as in Section 4.1.
(b) The two markers follow a mixture of two Gaussian copulas with student-t marignals (4 degrees of freedom;
parameters are scaled to retain the values of means and variances in the bivariate normal distributions above).
The case prevalence is 0.5 in both settings.
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2. For each simulated training set:
• Fit the data by the bivariate normal mixture model (5).
• Use the MLE to derive the classification rules for one single marker, the optimal linear composite test and the
optimal sequential composite test under two specificities, 0.8 and 0.9.
• Simulate one testing dataset with the same sample size and the same simulating distribution as the training
data, for each of the three values of the case prevalence, 0.25, 0.5 and 0.75.
• Apply the classification rules to each testing set and calculate the true positive fraction (TPF) and true negative
fraction (TNF).
3. Repeat steps above for 1000 times, for each of the three sample sizes (100, 200 and 400).
Table 2 listed the TPFs and TNFs of the three classification rules averaged over the 1000 experiments. The test based on
one single marker alone has a poor discriminating power. Both composite tests improve the accuracy substantially in terms
of a higher TPF under the pre-specified specificities in the training set. The optimal sequential composite test outperforms
the other two tests with the highest TPF and the accordant TPF, even when the multivariate normal assumption is violated
(Setting b). Note that when normal assumption holds (Setting a), the empirical sensitivities of both composite tests in the
testing set approach to the exact value as the sample size goes up.
Under both settings, different case prevalences in the new data do not affect the classification accuracy, but the optimal
sequential test would be more efficient when applied to a data with a greater case prevalence since more subjects can be
identified as case by one test at the first step of the test.
5. Discussion
In this paper, we develop a classification method from an alternative perspective based on multiple quantitative tests
without a gold standard. The constitution of the optimal sequential composite test is statistically equivalent to the
implementation of a sequence of tests discussed by Thompson [25]. Illustrated by the real data application and simulation
studies, for the data of the pattern shown in Figures 2 and 4, the optimal sequential composite test demonstrates a
considerable improvement in the discriminating power between case and non-case in view of the area under the ROC
curve (AUC). Moreover, it has an additional advantage of engaging fewer tests. This is especially desired when the tests
are costly or not applicable to all study subjects under some circumstances. The optimality of the composite test in this
article is purely based on the classification accuracy without considering risk or cost associated with the tests. Some
modifications of the optimizing system for the decision rule is needed if the risk or cost ought to be considered for
determining an optimal decision rule in some applications.
The sequential composite test in this work uses the “believe the positive” rule based on the biological mechanism in our
motivating example. It can be constructed by the “believe negative” rule accordingly in other applications. Also there has
been some works in the framework of group sequential design to evaluate diagnostic tests with a gold standard [40, 41].
Further topics could be to generalize this method to the design of clinical trials.
The sequential classification method is illustrated with two tests throughout the paper but it can be similarly designed for
the situation with more than two tests. It is, however, a mathematically challenging problem because finding the optimal
cut-off values may not be equivalently converted to the problem of solving a nonlinear system as it does for the two-test
case. The grid search is a straightforward option but it can be very numerically inefficient, especially for high dimensional
data. There is still a space for improving the numerical algorithm in order to accommodate an arbitrary number of tests.
The proposed method has a fundamental assumption of multivariate normal distribution for the test results in both
case and non-case groups. This assumption is likely violated in applications. In our second simulation study, when the
distributional assumption is violated, the predication based on the mis-specified model is quite accurate. When the data are
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Table 2. Summary of TPFs and TNFs in the simulation study in Section 4.2. The case prevalence π = 0.5 in the training
set and three different values in the testing set, 0.25, 0.5, and 0.75. Two specificities (Spe), 0.8 and 0.9, are used to derive
the classification rules in the training set.
Setting a
TPFs
pi = 0.25 pi = 0.5 pi = 0.75
Spe N 1 marker Linear Sequential 1 marker Linear Sequential 1 marker Linear Sequential
0.8 100 0.188 0.729 0.793 0.188 0.727 0.794 0.188 0.727 0.794
200 0.197 0.735 0.802 0.196 0.736 0.802 0.196 0.736 0.802
400 0.196 0.738 0.802 0.197 0.737 0.802 0.198 0.737 0.802
0.9 100 0.097 0.674 0.741 0.099 0.672 0.740 0.099 0.671 0.741
200 0.100 0.677 0.749 0.101 0.679 0.750 0.100 0.679 0.750
400 0.100 0.681 0.750 0.100 0.681 0.751 0.100 0.681 0.751
TNFs
pi = 0.25 pi = 0.5 pi = 0.75
Spe N 1 marker Linear Sequential 1 marker Linear Sequential 1 marker Linear Sequential
0.8 100 1.000 0.780 0.778 1.000 0.780 0.776 1.000 0.777 0.776
200 1.000 0.788 0.787 1.000 0.787 0.786 1.000 0.786 0.785
400 1.000 0.795 0.794 1.000 0.795 0.794 1.000 0.796 0.795
0.9 100 1.000 0.879 0.876 1.000 0.879 0.875 1.000 0.877 0.873
200 1.000 0.888 0.886 1.000 0.888 0.887 1.000 0.887 0.886
400 1.000 0.895 0.894 1.000 0.895 0.894 1.000 0.896 0.894
Fraction of subjects classified by one test only in the optimal sequential composite test (%)
pi = 0.25 pi = 0.5 pi = 0.75
Spe N 1 marker Linear Sequential 1 marker Linear Sequential 1 marker Linear Sequential
0.8 100 28.7 41.2 53.8
200 27.7 40.6 53.8
400 27.1 40.3 53.5
0.9 100 21.5 34.3 47.2
200 20.6 33.7 47.0
400 20.2 33.5 47.0
Setting b
TPFs
pi = 0.25 pi = 0.5 pi = 0.75
Spe N 1 marker Linear Sequential 1 marker Linear Sequential 1 marker Linear Sequential
0.8 100 0.164 0.752 0.822 0.164 0.752 0.823 0.164 0.751 0.823
200 0.163 0.756 0.827 0.163 0.757 0.827 0.163 0.758 0.828
400 0.159 0.771 0.838 0.161 0.770 0.838 0.161 0.771 0.839
0.9 100 0.085 0.697 0.770 0.085 0.696 0.770 0.085 0.695 0.770
200 0.081 0.701 0.774 0.082 0.701 0.775 0.081 0.702 0.775
400 0.077 0.718 0.788 0.077 0.717 0.788 0.077 0.717 0.788
TNFs
pi = 0.25 pi = 0.5 pi = 0.75
Spe N 1 marker Linear Sequential 1 marker Linear Sequential 1 marker Linear Sequential
0.8 100 0.998 0.814 0.793 0.998 0.814 0.793 0.997 0.813 0.792
200 0.997 0.821 0.801 0.998 0.821 0.801 0.998 0.821 0.801
400 0.998 0.830 0.808 0.998 0.831 0.808 0.998 0.831 0.809
0.9 100 0.999 0.888 0.863 0.999 0.887 0.864 0.999 0.885 0.862
200 0.999 0.895 0.874 0.999 0.895 0.874 0.999 0.894 0.873
400 0.999 0.904 0.881 0.999 0.904 0.881 0.999 0.904 0.881
Fraction of subjects classified by one test only in the optimal sequential composite test (%)
pi = 0.25 pi = 0.5 pi = 0.75
Spe N 1 marker Linear Sequential 1 marker Linear Sequential 1 marker Linear Sequential
0.8 100 27.7 41.6 55.6
200 26.8 41.1 55.7
400 26.4 41.3 56.2
0.9 100 22.2 35.8 49.5
200 21.4 35.4 49.6
400 21.2 35.6 50.2
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not normal, we could also estimate the mixing probability distributions nonparametrically using the method developed by
Hall and Zhou [34]. But Hall-Zhous’s estimation method is very complicated to implement and is restrictive. The tensor
spline-based sieve maximum likelihood estimation [42] of the multivariate distribution function is a compromise to the
Hall-Zhou’s nonparametric estimation of mixture distribution. Although the optimal sequential composite tests can still
be computed with the tensor spline-based sieve estimation in principle, the numerical implementation of the test is much
more demanding and challenging than the multivariate normal model. Moreover, the spline-based model would add more
complexity to studying the statistical properties of the test. Study and implementation of the spline-based model for the
optimal sequential composite test in this context are currently under our investigation.
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Appendices
A. Details of the EM algorithm in Section 2
The EM algorithm treats the exact case membership D as missing. Therefore, the complete data consist of
{(X1, D1), · · · , (Xn, Dn)}, and the complete-data log-likelihood is given by (6).
Let θ(i) denote the estimate of θ after the ith iteration of the EM algorithm.
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• E step: The E step computes the conditional expectation of la(θ) given the observed data (X1, . . . ,Xn) and the
current estimates of θ, θ(i),
E
(
la(θ)|θ(i)
)
=
n∑
k=1
{
Pr(Dk = 1|θ(i)) log πf1(X1k, X2k|θ1)+
Pr(Dk = 0|θ(i)) log(1− π)f0(X1k, X2k|θ0)
}
.
If we write
π˜
(i)
k = Pr(Dk = 1|θ(i)),
f
(i)
1 (X1k, X2k) = f1(X1k, X2k|θ(i)1 ),
f
(i)
0 (X1k, X2k) = f0(X1k, X2k|θ(i)0 ),
it is easy to show that
π˜
(i)
k =
π(i)f
(i)
1 (X1k, X2k)
π(i)f
(i)
1 (X1k, X2k) + (1− π(i))f (i)0 (X1k, X2k)
, (A.1)
and
E
(
la(θ)|θ(i)
)
=
n∑
k=1
π˜
(i)
k log πf1(X1k, X2k|θ1) + (1− π˜(i)k ) log(1− π)f0(X1k, X2k|θ0). (A.2)
• M step: The M step updates the estimate θ(i+1) for θ by maximizing E (la(θ)|θ(i)) in (A.2) with respect to θ. We
can show that θ(i+1) has the following explicit expression:
π(i+1) =
1
n
n∑
k=1
π˜
(i)
k , (A.3)
µ
(i+1)
1 =
1
nπ(i+1)
n∑
k=1
π˜
(i)
k Xk, (A.4)
V
(i+1)
1 =
1
nπ(i+1)
n∑
k=1
π˜
(i)
k (Xk − µ(i+1)1 )(Xk − µ(i+1)1 )T , (A.5)
µ
(i+1)
0 =
1
n(1 − π(i+1))
n∑
k=1
(1− π˜(i)k )Xk, (A.6)
V
(i+1)
0 =
1
n(1 − π(i+1))
n∑
k=1
(1− π˜(i)k )(Xk − µ(i+1)0 )(Xk − µ(i+1)0 )T , (A.7)
where Xk = (X1k, X2k)T .
B. Proof of Theorem 2.1
Since F1 and F0 are the cumulative distribution function of bivariate normal distributions, the function G(C, θ) is
continuously differentiable with respect to C and θ. Condition (8) is equivalent to the statement that the Jacobian matrix
∇CG(C0, θ0) is invertible by deriving the determinant of∇CG(C0, θ0) and setting it not equal to zero. Hence, according
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to the implicit function theorem [43], there exists an open set U containing θ0, an open set V containing C0, and a unique
continuous differentiable function g : U → V such that C = g(θ) and G(g(θ), θ) = 0 for all θ ∈ U .
Based on the MLE properties, it is known that θˆn →p θ0 and
√
n(θˆn − θ0)→d N(0, I−1). So for any ǫ > 0 and δ > 0,
there exists an N , such that n > N , Pr(|θˆn − θ0| > δ) < ǫ. This implies that for any n > N , θˆn ∈ U in probability,
and hence the proposed method for finding the cut-off Cˆn = (Cˆn,1, Cˆn,2) through solving for G(Cˆn, θˆn) = 0 results in
Cˆn = g(θˆn) in probability.
Further note that F1(C, θ) = F1(g(θ), θ) is a continuously differentiable function of θ, and consequently, by the
continuous mapping theorem and the delta method, we have
√
n (ŝenC − senC) =
√
n
(
F1(Cˆn, θˆn)− F1(C0, θ0)
)
=
√
n
(
F1(Cˆn, θˆn)− F1(C0, θˆn) + F1(C0, θˆn)− F1(C0, θ0)
)
=
√
n
(
∇CF1(C0, θˆn)(Cˆn −C0) +∇θF1(C0, θ0)(θˆn − θ0)
)
+ op(1)
=
√
n
(
∇CF1(C0, θˆn)∇θg(θ0)(θˆn − θ0) +∇θF1(C0, θ0)(θˆn − θ0)
)
+ op(1)
=
(
∇CF1(C0, θˆn)∇θg(θ0) +∇θF1(C0, θ0)
)√
n(θˆn − θ0)
→d N(0, BI−1BT ),
where
B = ∇CF1(C0, θ0)∇θg(θ0) +∇θF1(C0, θ0). (B.1)
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